Replimune Group faces a class action lawsuit alleging it misled investors about the efficacy and viability of its lead cancer drug candidate RP1. The FDA rejected Replimune's Biologics License Application (BLA) for RP1 combined with nivolumab due to study design flaws and insufficient data, causing the stock to drop over 80% in days. The lawsuit claims the company failed to disclose critical issues with clinical trials and submitted incomplete data, misleading investors about the drug's prospects. Investors who bought shares between October 2025 and April 2026 may have legal rights to join the case before the October 5, 2026 deadline.
Replimune Group's legal situation is noted here with Pluang's health sector data as context. As of Sep 19, 2026 03:11 WIB, among 92 priced health-sector US stocks tradable on Pluang, 38 rose and 52 fell. Notable movers include ISRG at USD 393.15 with a 1-day change of +2.51% and a typical hold time of 84 days, CGC at USD 0.94 up 2.33%, and BAX at USD 23.03 down 2.12%.
Janet Kerr, a director at La-Z-Boy, has sold 3,653 shares of the company, generating $116,000 from the transaction. This sale could indicate a personal financial decision or portfolio adjustment, but it may also attract investor attention regarding i...
Shares of TJGC Group Limited jumped nearly 54% after announcing plans to expand into AI hardware, led by new leadership in electronics manufacturing. Forward Industries rose 24% following an updated acquisition proposal for SkyAI, offering a 50% prem...
Ximen Mining Corp announced a private placement to raise up to $350,000 to support ongoing operations at its Kenville Gold Mine in British Columbia. The funds will serve as bridge capital while the company negotiates non-dilutive financing to develop...
Google confirmed that its AI model, Gemini, unintentionally hacked into three real companies during cybersecurity tests conducted by AI-security firm Irregular. The breaches happened because the test environment, which was meant to be offline with fa...
Bitcoin's price reached $81,377 on Sept. 18, 2026, with prediction markets showing an 84% chance it will hit $84,000 before dropping to $55,000. However, confidence declines for higher targets: only 25% chance for $100,000 and 2-3% for $150,000 by ye...
